HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3

Leukemia

Volumn 19, Issue 5, 2005, Pages 841-846

  Nagel, S ^a   Scherr, M ^b   Quentmeier, H ^a   Kaufmann, M ^a   Zaborski, M ^a   Drexler, H G ^a   MacLeod, R A F ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

E2F; HLXB9; Hodgkin; Homeobox; IL6; Polycomb

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HOMEODOMAIN PROTEIN; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN HLXB9; PROTEIN KINASE B; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; ENZYME ANALYSIS; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; HELA CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPORTER GENE; SIGNAL TRANSDUCTION;

EID: 18644375174     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403716     Document Type: Article

References (52)

1. Drexler HG. The leukemia-Lymphoma Cell Line Factsbook. San Diego: Academic Press, 2000.
2. Vener C, Guffanti A, Pomati M, Colombi M, Alietti A, La Targia ML et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 2000; 37: 333-339.
3. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 2002; 118: 195-201.
4. Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, Cockburn MG et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103: 3216-3221.
5. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NFκB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-2807.
6. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21: 4104-4113.
7. Ray A, Sassone-Corsi P, Sehgal PB. A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol Cell Biol 1989; 9: 5537-5547.
8. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10: 2327-2334.
9. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997; 19: 2899-2916.
10. Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 2000; 96: 2841-2848.
11. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003, 225-247.
12. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haler B, Behrmann I et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-770.
13. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027.
14. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 2003; 199: 201-207.
15. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157: 709-715.
16. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-881.
17. Sanchez-Beato M, Sanchez E, Garcia JF, Perez-Rosado A, Montoya MC, Fraga M et al. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J Pathol 2004; 204: 528-537.
18. Bürglin T. A comprehensive classification of homeobox genes. In: Duboule (ed), Guidebook to the Homeobox Genes. Oxford: Oxford University Press, 1994.
19. van Oostveen J, Bijl J, Raaphorst F, Walboomers J, Meijer C. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia 1999; 13: 1675-1690.
20. Owens BM, Hawley RG. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells 2002; 20: 364-379.
21. Holland PW. Beyond the Hox: how widespread is homeobox gene clustering? J Anat 2001; 199: 13-23.
22. Nagel S, Kaufmann M, Drexler HG, MacLeod RAF. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res 2003; 63: 5329-5334.
23. MacLeod RAF, Nagel S, Kaufmann M, Janssen JW, Drexler HG. Activation of HOX11L2 by juxtaposition with 3′-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t(5;14)(q35;q32.2). Genes Chromosomes Cancer 2003; 37: 84-91.
24. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92: 1308-1316.
25. Vult von Steyern F, Martinov V, Rabben I, Nja A, de Lapeyriere O, Lomo T. The homeodomain transcription factors Islet 1 and HB9 are expressed in adult alpha and gamma motoneurons identified by selective retrograde tracing. Eur J Neurosci 1999; 11: 2093-2102.
26. Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH. Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice. Nat Genet 1999; 23: 71-75.
27. Ross AJ, Ruiz-Perez V, Wang Y, Hagan DM, Scherer S, Lynch SA et al. A homeobox gene, HLXB9, is the major locus for dominantly inherited sacral agenesis. Nat Genet 1998; 20: 358-361.
28. Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001; 61: 5374-5377.
29. Nagel S, Kaufmann M, Scherr M, Drexler HG, MacLeod RAF. Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1). Genes Chromosomes Cancer 2005; 42: 170-178.
30. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13: 1383-1389.
31. Vinante F, Rigo A, Scupoli MT, Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. Blood 2002; 99: 52-60.
32. Gao AC, Lou W, Isaacs JT. Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene. Clin Cancer Res 2000; 6: 493-497.
33. Leutz A, Damm K, Sterneck E, Kowenz E, Ness S, Frank R et al. Molecular cloning of the chicken myelomonocytic growth factor (cMGF) reveals relationship to interleukin 6 and granulocyte colony stimulating factor. EMBO J 1989; 8: 175-181.
34. Kowenz-Leutz E, Herr P, Niss K, Leutz A. The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation. Cell 1997; 91: 185-195.
35. Lee SK, Jurata LW, Funahashi J, Ruiz EC, Pfaff SL. Analysis of embryonic motoneuron gene regulation: derepression of general activators function in concert with enhancer factors. Development 2004; 131: 3295-3306.
36. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945-3950.
37. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145: 515-525.
38. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004; 64: 5251-5260.
39. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815-822.
40. Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol 2001; 21: 5797-5805.
41. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627-1630.
42. Brennan P, Babbage JW, Thomas G, Cantrell D. p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol 1999; 19: 4729-4738.
43. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 10848-10853.
44. Gao N, Zhang Z, Jiang BH, Shi X. Role of Pl3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124-1132.
45. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 2000; 20: 3626-3632.
46. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004; 29: 409-417.
47. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681-689.
48. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
49. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002; 13: 1977-2000.
50. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 1998; 12: 2120-2130.
51. Garcia E, Marcos-Gutierrez C, del Mar Lorente M, Moreno JC, Vidal M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J 1999; 18: 3404-3418.
52. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 2002; 21: 5775-5786.